Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• Metastatic basal cell carcinoma (BCC) is an extremely rare but aggressive form of a common skin cancer.
• Early treatments relied on chemotherapy, but recent advances focus on targeted therapies.
• The Hedgehog signaling pathway is critical for BCC development, and its dysregulation drives tumorigenesis.

Purpose of the Study:

• To review current therapeutic strategies for metastatic BCC.
• To highlight the role of Hedgehog pathway inhibitors and immune checkpoint blockade.
• To present a case study demonstrating the efficacy of combination therapy.

Main Methods:

• Literature review of therapeutic developments for metastatic BCC.
• Analysis of the role of Hedgehog pathway inhibitors (e.g., vismodegib, sonidegib).
• Discussion of immune-related targets like high tumor mutational burden and PD-L1 amplification.

Main Results:

• Hedgehog pathway inhibitors (SMO inhibitors) are approved and effective treatments.
• Immune checkpoint inhibitors (PD-1/PD-L1) are potential therapies, especially in tumors with high mutational burden.
• A patient with advanced, unresectable BCC achieved complete remission with combination therapy.

Conclusions:

• Targeted therapies, including Hedgehog inhibitors and immune checkpoint blockade, have significantly improved metastatic BCC treatment.
• Understanding the genomic landscape of metastatic BCC can guide the development of novel therapeutic combinations.
• Combination approaches hold promise for enhancing patient responses and outcomes in rare, advanced BCC cases.